1 day Sage Therapeutics: Looks Like A ‘Strong Buy’ With Zurzuvae’s Potential And Biogen’s Bid Seeking Alpha

   X     

1 week Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen’s Offer & Other Updates Zacks

   X     

1 week Sage Therapeutics: Biogen’s Unsolicited Bid Is Best Step Forward For Shareholders Seeking Alpha

   X     

1 week Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) Seeking Alpha

   X     

1 week Biogen CEO sees no burning need for more acquisitions Investing.com

   X     

1 week Biogen Offers to Buy Remaining Stake in Sage Therapeutics Zacks

   X     

2 weeks Biogen Wants to Buy Its Partner Sage for Almost No Premium Yahoo Finance

   X     

2 weeks Biogen proposes to buy remaining stake in Sage in $442 million deal Investing.com

   X     

3 weeks Biogen Holds On, But Growth Slips Through Its Fingers Seeking Alpha

   X     

3 weeks Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges Investing.com

   X     

3 weeks Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term Zacks

   X     

3 weeks Beaten Down Biogen Stock Looks Attractive At Current Levels Seeking Alpha

   X     

1 month BMO cuts rating on Merck and Biogen, on lack of near term catalyst Investing.com

   X     

1 month Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead Investing.com

   X     

1 month Private Medicare plans must cover Biogen’s ALS drug, US agency says Investing.com

   X     

1 month Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock Zacks

   X     

2 months Biogen cut at Jefferies as ‘2025 has a tough setup’ Investing.com

   X     

2 months Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript Seeking Alpha

   X     

2 months Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe Zacks

   X     

2 months Here’s Why Biogen Inc. (BIIB) is a Strong Value Stock Zacks

   X     

3 months Are Investors Undervaluing Biogen (BIIB) Right Now? Zacks

   X     

3 months Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter Seeking Alpha

   X     

3 months Biogen Beats on Q3 Earnings & Sales, Raises ’24 EPS View Zacks

   X     

3 months Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript Seeking Alpha

   X     

3 months Biogen lifts annual profit forecast as new treatments boost earnings Investing.com

   X     

3 months Biogen (NASDAQ:BIIB) Releases FY 2024 Earnings Guidance MarketBeat

   X     

3 months Short Interest in Biogen Inc. (NASDAQ:BIIB) Grows By 7.7% MarketBeat

   X     

3 months Biogen raises annual profit forecast as new treatments boost earnings Investing.com

   X     

3 months Biogen Sinks. Why A Surprise Boost From Its Alzheimer’s Drug Wasn’t Enough. Investor's Business Daily

   X     

3 months Alphabet, Biogen, Humana rise premarket; AMD, Eli Lilly fall Investing.com

   X     

3 months Biogen (NASDAQ:BIIB) Sees Unusually-High Trading Volume – Here’s What Happened MarketBeat

   X     

3 months Greenleaf Trust Sells 3,475 Shares of Biogen Inc. (NASDAQ:BIIB) MarketBeat

   X     

3 months Will New Drugs Help Biogen Surpass Q3 Earnings Estimates? Zacks

   X     

3 months International Assets Investment Management LLC Has $695.87 Million Stake in Biogen Inc. (NASDAQ:BIIB) MarketBeat

   X     

3 months The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen Zacks

   X     

3 months The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen Zacks

   X     

3 months Biogen Inc. (NASDAQ:BIIB) Shares Bought by Raymond James & Associates MarketBeat

   X     

3 months Arlington Partners LLC Acquires 4,902 Shares of Biogen Inc. (NASDAQ:BIIB) MarketBeat

   X